Prescott Group Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Prescott Group Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$388K	Hold	869	–	–	0.04%	245
2025 Q4	$394K	Hold	869	–	–	0.04%	263
2025 Q3	$340K	Hold	869	–	–	0.04%	231
2025 Q2	$387K	Buy	869 +272	+46%	+$125K	0.05%	231
2025 Q1	$289K	Buy	+597	New	+$278K	0.04%	210
2018 Q4	–	Sell	-5,000	Closed	-$964K	–	259
2018 Q3	$964K	Hold	5,000	–	–	0.19%	120
2018 Q2	$850K	Hold	5,000	–	–	0.16%	136
2018 Q1	$815K	Hold	5,000	–	–	0.18%	131
2017 Q4	$749K	Hold	5,000	–	–	0.16%	119
2017 Q3	$760K	Buy	+5,000	New	+$753K	0.15%	120

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Prescott Group Capital Management's VRTX Position: Q1 2026 in Review

Prescott Group Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 869 shares worth $388K. The position accounts for 0.04% of the portfolio, ranked #245.

Prescott Group Capital Management first reported a position in VRTX in Q3 2017 and has held it in 10 quarters since. The position peaked at $964K in Q3 2018. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Prescott Group Capital Management held 869 shares of Vertex Pharmaceuticals worth $388K as of Q1 2026.
Prescott Group Capital Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.04% of Prescott Group Capital Management's portfolio in Q1 2026, its #245 holding.
Prescott Group Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 10 quarters since.
Prescott Group Capital Management's Vertex Pharmaceuticals position peaked at $964K in Q3 2018.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Prescott Group Capital Management's 13F filing for Q1 2026, filed 7 May 2026.